Log in to add personal notes on this page.
Peroxisomes handle the lipids other organelles cannot: they break down very long-chain fatty acids (VLCFAs), too long for mitochondria, shorten the branched dietary phytanic acid, make plasmalogens for cell membranes (especially brain and lung), and help make bile acids. They are built by peroxins, which also import their enzymes. A defect in building or filling the organelle affects every pathway at once, while a defect in one enzyme or transporter affects one, and that difference is what the labs read. A defect in the PTS2 receptor falls between the two, because it strands only the few enzymes that receptor imports.
- Build and fill the peroxisome: peroxins (PEX genes) assemble the membrane and import matrix enzymes, using the PTS1 receptor (PEX5) and the PTS2 receptor (PEX7). Blocked in Zellweger spectrum disorders; PEX7 alone in RCDP type 1, where the peroxisome forms and imports its PTS1 enzymes but not its PTS2 enzymes, among them phytanoyl-CoA hydroxylase and alkyldihydroxyacetonephosphate synthase.
- VLCFAs → peroxisomal beta-oxidation → shorter fatty acids: the transporter ALDP (ABCD1) carries VLCFAs into the peroxisome first. Blocked in X-linked adrenoleukodystrophy.
- phytanoyl-CoA → 2-hydroxyphytanoyl-CoA → pristanic acid + CO2: phytanoyl-CoA hydroxylase (PHYH), imported by the PTS2 receptor, starts alpha-oxidation; 2-hydroxyphytanoyl-CoA lyase and an aldehyde dehydrogenase finish it. The carboxyl carbon leaves as CO2, so beta-oxidation can follow. Blocked in Refsum disease. Lost from the peroxisome when PEX7 fails (in the PEX7 form of Refsum disease and in RCDP type 1), because the enzyme is never imported.
- fatty acyl-CoA → fatty alcohol: fatty acyl-CoA reductase 1 (FAR1), which supplies the fatty alcohol for plasmalogen synthesis. Blocked in FAR1-related disorder.
- dihydroxyacetone phosphate → 1-acyl-DHAP → 1-alkyl-DHAP: dihydroxyacetone phosphate acyltransferase (GNPAT), then alkyldihydroxyacetonephosphate synthase (AGPS) swaps in the fatty alcohol to make the ether bond. Plasmalogens are the ether lipids that result, carrying the fatty alcohol at their first position. Blocked in RCDP types 2 and 3 (the GNPAT and AGPS forms). The synthase is also lost in RCDP type 1, because PEX7 is the receptor that imports it.
- Bile acid synthesis: the C27 intermediates THCA and DHCA become the C24 bile acids. THCA and DHCA accumulate in Zellweger spectrum disorders, and giving the C24 bile acid turns the pathway down by feedback.
- Zellweger spectrum disorders (AR, 13 PEX genes, PEX1 most often): the peroxins that build the membrane or import the matrix enzymes fail, not any one enzyme, so every peroxisomal pathway is affected at once. Severe disease brings profound hypotonia, seizures, liver disease, stippled epiphyses, and death in the first year; milder forms (once called neonatal adrenoleukodystrophy and infantile Refsum disease), whose peroxins keep some function, survive longer.
- X-linked adrenoleukodystrophy: the ALDP transporter fails, so VLCFAs, above all C26:0, cannot enter the peroxisome to be broken down. They accumulate in all tissues and do most harm in the nervous system and adrenal cortex, as childhood cerebral disease, adrenomyeloneuropathy, or adrenal insufficiency alone. Most heterozygous females (65% to 80%) develop a milder spinal cord disease in adulthood.
- Refsum disease (AR): phytanic acid accumulates while VLCFAs stay normal, giving retinitis pigmentosa, anosmia, neuropathy, ataxia, and ichthyosis. More than 90% of cases lack the hydroxylase itself (PHYH); under 10% have a PEX7 defect, a targeting failure that keeps the hydroxylase out of the peroxisome. Because the substrate comes only from the diet, restricting it helps.
- RCDP (AR): plasmalogens fall, giving rhizomelic limb shortening, stippled growth plates, cataracts, and severe intellectual disability; VLCFAs stay normal. Type 1, the PEX7 form, is an import defect rather than an enzyme deficiency. Its PTS2 enzymes stay in the cytosol and are degraded, so phytanic acid also rises once the diet contains it. The GNPAT and AGPS forms are deficiencies of the plasmalogen enzymes themselves.
- FAR1-related disorder: biallelic loss of the reductase lowers plasmalogens (an RCDP-like picture without rhizomelia); de novo p.Arg480 variants break the plasmalogen feedback that limits the enzyme, so plasmalogens rise, with spastic paraparesis and cataracts.
- Several markers abnormal at once (raised VLCFAs, low plasmalogens, raised pipecolic acid and C27 bile acid intermediates, and phytanic acid once the diet contains it) points to a failure to build or fill the organelle, as in Zellweger spectrum. Milder forms can have near-normal markers, so a normal screen does not exclude it and molecular testing is needed.
- One pathway abnormal names the single defect: VLCFAs alone in X-ALD (C26:0-lysophosphatidylcholine on newborn screening), phytanic acid with normal VLCFAs in Refsum disease, low red cell plasmalogens with normal VLCFAs in RCDP. In RCDP type 1, phytanic acid also rises once the diet contains it, because PEX7 imports phytanoyl-CoA hydroxylase as well as the plasmalogen enzyme.
- Plasmalogens high, not low, point to the dominant FAR1 disorder.
- Phytanic acid is normal in a newborn with any of these, because it comes only from food; a normal newborn value does not exclude Refsum disease or Zellweger spectrum.
Refsum: Retinitis pigmentosa, fat (phytanic acid) restriction in the diet, loss of smell.